Under the agreement, Synthes will use Lilly’s early stage compounds for orthopedic trauma, spine, craniomaxillofacial and reconstructive indications. The compounds have pre-clinical and in some cases clinical data to show regenerative bone capabilities.
The two companies will jointly develop the site-specific osteoinductive products based on Synthes’ biomaterials and Lilly’s biologics or pharmaceuticals businesses. The companies will also jointly conduct and fund the evaluation of additional orthopedic uses for Lilly’s osteoporosis drug Forteo.
Read the release on the partnership between Lilly and Synthes.
Related Articles on Orthopedic Device Company Partnerships:
DSM Biomedical Continues Spinelab Partnership
DJO Partners With Lima to Expand U.S. Market Offerings
InVivo Therapeutics Partners With The Miami Project to Cure Paralysis
